Superior Group of Companies (SGC) 10-Q 6 Nov 24 2024 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Oct. 31, 2024
Document Information [Line Items]
Entity Central Index Key	0000095574
Entity Registrant Name	SUPERIOR GROUP OF COMPANIES, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-05869
Entity Incorporation, State or Country Code	FL
Entity Tax Identification Number	11-1385670
Entity Address, Address Line One	200 Central Avenue, Suite 2000
Entity Address, City or Town	St. Petersburg
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33701
City Area Code	727
Local Phone Number	397-9611
Title of 12(b) Security	Common Stock $0.001 par value per share
Trading Symbol	SGC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		16,341,231

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net sales	$ 149,690	$ 136,126	$ 420,268	$ 396,061
Costs and expenses:
Cost of goods sold	89,144	82,928	253,650	248,159
Selling and administrative expenses	52,215	47,246	149,339	134,007
Other periodic pension costs	189	214	567	642
Interest expense	1,569	2,464	4,897	7,658
Costs and Expenses	143,117	132,852	408,453	390,466
Income before income tax expense	6,573	3,274	11,815	5,595
Income tax expense	1,170	160	1,900	380
Net income	$ 5,403	$ 3,114	$ 9,915	$ 5,215
Net income per share:
Basic (in dollars per share)	$ 0.34	$ 0.19	$ 0.62	$ 0.33
Diluted (in dollars per share)	$ 0.33	$ 0.19	$ 0.6	$ 0.32
Weighted average shares outstanding during the period:
Basic (in shares)	16,107,549	15,992,792	16,118,885	15,954,264
Diluted (in shares)	16,543,990	16,155,355	16,588,914	16,132,832
Other comprehensive income (loss), net of tax:
Recognition of net losses included in net periodic pension costs	$ 23	$ 41	$ 68	$ 123
Foreign currency translation adjustment	530	(424)	(1,201)	160
Other comprehensive income (loss)	553	(383)	(1,133)	283
Comprehensive income	$ 5,956	$ 2,731	$ 8,782	$ 5,498
Cash dividends per common share (in dollars per share)	$ 0.14	$ 0.14	$ 0.42	$ 0.42

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 18,373	$ 19,896
Accounts receivable, less allowance for doubtful accounts of $3,836 and $4,237, respectively	98,822	103,494
Inventories	93,771	98,067
Contract assets	50,326	48,715
Prepaid expenses and other current assets	10,177	9,188
Total current assets	271,469	279,360
Property, plant and equipment, net	42,859	46,890
Operating lease right-of-use assets	16,282	17,909
Deferred tax asset	12,333	12,356
Intangible assets, net	47,959	51,160
Other assets	16,448	14,775
Total assets	407,350	422,450
Current liabilities:
Accounts payable	46,292	50,520
Other current liabilities	42,381	43,978
Current portion of long-term debt	5,625	4,688
Current portion of acquisition-related contingent liabilities	740	1,403
Total current liabilities	95,038	100,589
Long-term debt	78,755	88,789
Long-term pension liability	13,517	13,284
Long-term acquisition-related contingent liabilities	0	557
Long-term operating lease liabilities	11,295	12,809
Other long-term liabilities	9,236	8,784
Total liabilities	207,841	224,812
Commitments and contingencies (Note 5)
Shareholders’ equity:
Preferred stock, $.001 par value - authorized 300,000 shares (none issued)	0	0
Common stock, $.001 par value - authorized 50,000,000 shares, issued and outstanding 16,331,962 and 16,564,712 shares, respectively	16	16
Additional paid-in capital	81,859	77,443
Retained earnings	121,052	122,464
Accumulated other comprehensive loss, net of tax:
Pensions	(1,054)	(1,122)
Foreign currency translation adjustment	(2,364)	(1,163)
Total shareholders’ equity	199,509	197,638
Total liabilities and shareholders’ equity	$ 407,350	$ 422,450

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accounts receivable, allowance for doubtful accounts	$ 3,836	$ 4,237
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	300,000	300,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	16,331,962	16,564,712
Common stock, shares outstanding (in shares)	16,331,962	16,564,712

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Restricted Stock [Member] Common Stock [Member]	Restricted Stock [Member] Additional Paid-in Capital [Member]	Restricted Stock [Member] Retained Earnings [Member]	Restricted Stock [Member] AOCI Attributable to Parent [Member]	Restricted Stock [Member]	Performance Shares [Member] Common Stock [Member]	Performance Shares [Member] Additional Paid-in Capital [Member]	Performance Shares [Member] AOCI Attributable to Parent [Member]	Performance Shares [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2022										16,376,683
Balance at Dec. 31, 2022										$ 16	$ 72,615	$ 122,979	$ (3,011)	$ 192,599
Common shares issued upon exercise of options and SARs, net (in shares)										12,118
Common shares issued upon exercise of options and SARs, net										$ 0	97	0	0	97
Share-based compensation expense										0	3,523	0	0	3,523
Share-based compensation expense										0	3,523	0	0	3,523
Written put options										0	280	0	0	280
Cash dividends declared										0	0	(6,886)	0	(6,886)
Net income										0	0	5,215	0	5,215
Pensions, net of taxes										0	0	0	123	123
Change in currency translation adjustment, net of taxes										0	0	0	160	160
Restricted shares issued, net of forfeitures (in shares)	117,025
Restricted shares issued, net of forfeitures	$ 0	$ 0	$ 0	$ 0	$ 0
Performance based shares issued (in shares)	117,025
Written put options										$ 0	(280)	0	0	(280)
Balance (in shares) at Sep. 30, 2023										16,505,826
Balance at Sep. 30, 2023										$ 16	76,515	121,308	(2,728)	195,111
Balance (in shares) at Jun. 30, 2023										16,499,312
Balance at Jun. 30, 2023										$ 16	75,078	120,490	(2,345)	193,239
Common shares issued upon exercise of options and SARs, net (in shares)										6,514
Common shares issued upon exercise of options and SARs, net										$ 0	54	0	0	54
Share-based compensation expense										0	1,103	0	0	1,103
Share-based compensation expense										0	1,103	0	0	1,103
Written put options										0	280	0	0	280
Cash dividends declared										0	0	(2,296)	0	(2,296)
Net income										0	0	3,114	0	3,114
Pensions, net of taxes										0	0	0	41	41
Change in currency translation adjustment, net of taxes										0	0	0	(424)	(424)
Written put options										$ 0	(280)	0	0	(280)
Balance (in shares) at Sep. 30, 2023										16,505,826
Balance at Sep. 30, 2023										$ 16	76,515	121,308	(2,728)	$ 195,111
Balance (in shares) at Dec. 31, 2023										16,564,712				16,564,712
Balance at Dec. 31, 2023										$ 16	77,443	122,464	(2,285)	$ 197,638
Common shares issued upon exercise of options and SARs, net										0	1,331	(213)	0	1,118
Share-based compensation expense										0	2,905	0	0	2,905
Share-based compensation expense										0	2,905	0	0	2,905
Written put options										0	(2,407)	0	0	(2,407)
Cash dividends declared										0	0	(6,994)	0	(6,994)
Net income										0	0	9,915	0	9,915
Pensions, net of taxes										0	0	0	68	68
Change in currency translation adjustment, net of taxes										$ 0	0	0	(1,201)	$ (1,201)
Common shares issued upon exercise of options and SARs, net (in shares)										116,438				122,395
Common shares repurchased and retired (in shares)										(451,786)
Common shares repurchased and retired											(2,227)	(4,120)	0	$ (6,347)
Restricted shares issued, net of forfeitures (in shares)	92,702					9,896
Restricted shares issued, net of forfeitures	$ 0	0	0	0	0
Performance based shares issued (in shares)	92,702					9,896
Performance based shares issued						$ 0	$ 0	$ 0	$ 0
Written put options										$ 0	2,407	0	0	$ 2,407
Balance (in shares) at Sep. 30, 2024										16,331,962				16,331,962
Balance at Sep. 30, 2024										$ 16	81,859	121,052	(3,418)	$ 199,509
Balance (in shares) at Jun. 30, 2024										16,792,577
Balance at Jun. 30, 2024										$ 16	82,759	122,106	(3,971)	200,910
Common shares issued upon exercise of options and SARs, net										0	42	0	0	42
Share-based compensation expense										0	1,285	0	0	1,285
Share-based compensation expense										0	1,285	0	0	1,285
Cash dividends declared										0	0	(2,337)	0	(2,337)
Net income										0	0	5,403	0	5,403
Pensions, net of taxes										0	0	0	23	23
Change in currency translation adjustment, net of taxes										$ 0	0	0	530	530
Common shares issued upon exercise of options and SARs, net (in shares)										3,092
Common shares repurchased and retired (in shares)										(451,786)
Common shares repurchased and retired										$ 0	(2,227)	(4,120)	0	$ (6,347)
Restricted shares issued, net of forfeitures (in shares)	(11,921)
Restricted shares issued, net of forfeitures	$ 0	$ 0	$ 0	$ 0	$ 0
Performance based shares issued (in shares)	(11,921)
Balance (in shares) at Sep. 30, 2024										16,331,962				16,331,962
Balance at Sep. 30, 2024										$ 16	$ 81,859	$ 121,052	$ (3,418)	$ 199,509

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Cash dividends declared, per share (in dollars per share)	$ 0.14	$ 0.14	$ 0.42	$ 0.42
Pensions, tax	$ 8	$ 13	$ 23	$ 41
Change in currency translation adjustment, tax	0	0	0	0
Pensions, tax	8	13	23	41
Change in currency translation adjustment, tax	$ 0	$ 0	$ 0	$ 0

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 9,915	$ 5,215
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	9,872	10,331
Inventory write-downs	1,893	1,609
Provision for bad debts - accounts receivable	251	64
Share-based compensation expense	2,905	3,523
Change in fair value of acquisition-related contingent liabilities	363	(442)
Change in fair value of written put options	653	(460)
Changes in assets and liabilities:
Accounts receivable	3,891	9,650
Contract assets	(1,671)	6,208
Inventories	2,241	18,280
Prepaid expenses and other current assets	(1,292)	3,462
Other assets	(959)	(844)
Accounts payable and other current liabilities	(4,292)	2,148
Payment of acquisition-related contingent liabilities	(686)	(279)
Long-term pension liability	325	561
Other long-term liabilities	1,088	362
Net cash provided by operating activities	24,497	59,388
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(2,911)	(4,023)
Net cash used in investing activities	(2,911)	(4,023)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from borrowings of debt	31,000	4,000
Repayment of debt	(40,281)	(51,813)
Debt issuance costs	0	(300)
Payment of cash dividends	(6,994)	(6,886)
Payment of acquisition-related contingent liabilities	(897)	(553)
Proceeds received on exercise of stock options	1,118	97
Common shares repurchased and retired	(6,346)	0
Net cash used in financing activities	(22,400)	(55,455)
Effect of currency exchange rates on cash	(709)	97
Net increase (decrease) in cash and cash equivalents	(1,523)	7
Cash and cash equivalents balance, beginning of period	19,896	17,722
Cash and cash equivalents balance, end of period	$ 18,373	$ 17,729

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1 : Description of business Superior Group of Companies, Inc. (together with its subsidiaries, “the Company,” “Superior,” “we,” “our,” or “us”) was organized in 1920 1922 1998, May 3, 2018, Superior’s Branded Products segment, primarily through its signature marketing brands BAMKO® and HPI®, produces and sells customized merchandising solutions, promotional products and branded uniform programs. Branded products are manufactured through third Superior’s Healthcare Apparel segment, primarily through its signature marketing brands Fashion Seal Healthcare®, Wink® and CID Resources, manufactures (through third Superior’s Contact Centers segment, through multiple The Office Gurus® entities, including subsidiaries in El Salvador, Belize, Jamaica, Dominican Republic and the United States (collectively, “TOG”), provides outsourced, nearshore business process outsourcing, contact and call-center support services to North American customers. Basis of presentation The accompanying unaudited condensed consolidated financial statements of Superior included herein have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") ("U.S." or "United States") and the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. Intercompany items have been eliminated in consolidation. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10 December 31, 2023 not The Company refers to the condensed consolidated financial statements collectively as “financial statements,” and individually as “statements of comprehensive income (loss),” “balance sheets,” “statements of shareholders’ equity,” and “statements of cash flows” herein. Reclassifications The accompanying financial statements for the previous year contain certain reclassifications. Reclassifications impact the reporting of accounts receivable-other within the condensed consolidated balance sheets and statements of cash flows as well as the presentation of segment performance as described within Note 9 no Written Put Options During the second 2022, 480, Distinguishing Liabilities from Equity December 31, 2023, twenty-four nine September 30, 2024 Recent Accounting Pronouncements We consider the applicability and impact of all Accounting Standard Updates (“ASUs”). ASUs not not Recently Issued Accounting Pronouncements Not In November 2023, 2023 07, "Segment Reporting (Topic 280 Improvements to Reportable Segment Disclosures" December 15, 2023, December 15, 2024. 2023 07 December 31, 2024 no not In December 2023, 2023 09, "Income Taxes (Topic 740 Improvements to Income Tax Disclosures" December 15, 2024, January 1, 2025. not not

Note 2 - Inventories

Note 2 - Inventories	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	2 Inventories consisted of the following amounts (in thousands): September 30, December 31, 2024 2023 Finished goods $ 67,416 $ 72,370 Work in process 1,462 671 Raw materials 24,893 25,026 Inventories $ 93,771 $ 98,067

Note 3 - Long-term Debt

Note 3 - Long-term Debt	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Long-Term Debt [Text Block]	3 Debt consisted of the following (in thousands): September 30, December 31, 2024 2023 Credit Facilities: Revolving credit facility due August 2027 $ 19,000 $ 25,000 Term loan due August 2027 66,094 69,375 85,094 94,375 Less: Payments due within one year included in current liabilities 5,625 4,688 Debt issuance costs 714 898 Long-term debt less current maturities $ 78,755 $ 88,789 On August 23, 2022, August 2027 Obligations outstanding under the Credit Facilities accrue interest at a variable rate equal to the secured overnight financing rate ("SOFR") plus an adjustment between 0.10% and 0.25% (depending on the applicable interest period) plus a margin between 1.0% and 2.0% (depending on the Company’s net leverage ratio). The weighted average interest rate on our outstanding borrowings under the Credit Facilities was 6.0% as of September 30, 2024 September 30, 2024 Contractual principal payments for the term loan are as follows: remainder of 2024 2025 2026 2027 not The Credit Facilities are secured by substantially all of the operating assets of the Company, and the Company’s obligations under the Credit Facilities are guaranteed by all of its domestic subsidiaries. The Company’s obligations under the Credit Facilities are subject to acceleration upon the occurrence of an event of default as defined in the Credit Agreement. The Credit Agreement contains customary events of default and negative covenants, including but not 1.0 not 1.0. four September 30, 2024

Note 4 - Net Sales

Note 4 - Net Sales	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4 For our Branded Products and Healthcare Apparel segments, revenue is primarily generated from the sale of finished products to customers. Revenues for our Branded Products and Healthcare Apparel segments are recognized when the performance obligations under the contract terms are satisfied. For certain contracts with customers in which the Company has an enforceable right to payment for goods with no not For our Contact Centers segment, revenue is generated from providing our customers with contact center services. Revenue for our Contact Centers segment is recognized as services are delivered. Revenue is measured at the amount of consideration we expect to receive in exchange for the goods or services. Variable consideration for estimated returns, allowances and other price variances is recorded based upon historical experience and current allowance programs. Contract terms may not not one one For further information regarding our net sales disaggregated by reportable segment see Note 9 Contract Assets and Contract Liabilities The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers (in thousands): September 30, December 31, 2024 2023 Accounts receivable $ 98,822 $ 103,494 Current contract assets 50,326 48,715 Current contract liabilities 2,845 5,346 Contract assets relate to goods produced without an alternative use for which the Company has an enforceable right to payment but which has not December 31, 2023 nine September 30, 2024 nine September 30, 2024 December 31, 2023.

Note 5 - Contingencies

Note 5 - Contingencies	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	5 – Contingencies: The purchase price to acquire substantially all of the assets of Sutter’s Mill Specialties, Inc. (“Sutter’s Mill”) in December 2021 2022 2024. July 2023, first 2024. May 2022 April 2025. September 30, 2024 third 2025. third 2024, 2023 may may The Company is involved in various legal actions and claims arising from the normal course of business. In the opinion of management, the ultimate outcome of these matters is not

Note 6 - Share-based Compensati

Note 6 - Share-based Compensation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	6 : Share-based compensation expense is recorded in selling and administrative expense in the statements of comprehensive income. The following table details the share-based compensation expense by type of award for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Stock options and SARs $ 289 $ 319 $ 784 $ 1,018 Restricted stock 582 599 1,550 1,956 Performance shares 414 185 571 549 Total share-based compensation expense $ 1,285 $ 1,103 $ 2,905 $ 3,523 Stock Options and Stock Appreciation Rights (“SARs”) The Company grants stock options and stock-settled SARs to employees that allow them to purchase shares of the Company’s common stock. Stock options are also granted to outside members of the Board of Directors of the Company. The Company determines the fair value of stock options and SARs at the date of grant using the Black-Scholes valuation model. All stock options and SARs vest between one three five ten 2013 “2013 2022 “2022 A summary of stock option transactions during the nine September 30, 2024 Weighted Average Aggregate No. of Weighted Average Remaining Life Intrinsic Value Shares Exercise Price (in years) (in thousands) Outstanding, January 1, 2024 953,176 $ 14.73 2.80 $ 1,718 Granted (1) 183,800 14.38 Exercised (122,395 ) 10.71 Lapsed or cancelled (199,984 ) 16.49 Outstanding, September 30, 2024 814,597 14.82 3.26 2,165 Exercisable, September 30, 2024 341,469 18.59 2.22 494 ( 1 The weighted average grant date fair value of stock options granted was $4.27 per share. As of September 30, 2024 A summary of stock-settled SARs transactions during the nine September 30, 2024 Weighted Average Aggregate No. of Weighted Average Remaining Life Intrinsic Value Shares Exercise Price (in years) (in thousands) Outstanding, January 1, 2024 292,508 $ 14.35 2.07 $ 506 Granted (1) 79,128 13.84 Exercised (17,920 ) 8.48 Lapsed or cancelled (81,770 ) 19.23 Outstanding, September 30, 2024 271,946 13.12 2.34 832 Exercisable, September 30, 2024 137,742 13.37 0.79 479 ( 1 The weighted average grant date fair value of SARs granted was $3.80 per share. As of September 30, 2024 Restricted Stock The Company has granted shares of restricted stock to directors and certain employees, which vest at a specified future date, generally after three five 2013 2022 A summary of restricted stock transactions during the nine September 30, 2024 Weighted Average No. of Grant Date Shares Fair Value Outstanding, January 1, 2024 428,366 $ 18.14 Granted 146,303 14.77 Vested (79,322 ) 23.71 Forfeited (34,029 ) 19.75 Outstanding, September 30, 2024 461,318 15.99 As of September 30, 2024 Performance Shares The Company has granted performance shares, which either contain only service-based vesting conditions or service-based and performance-based vesting conditions. The service-based awards vest after the service period is met, which is generally three five five 2013 2022 On May 1, 2024, 2022 May 6, 2024. one four January 1, 2024, thirty 30 May 10, 2024 twelve 12 A summary of performance share transactions during the nine September 30, 2024 Weighted Average No. of Grant Date Shares Fair Value Outstanding, January 1, 2024 283,521 $ 18.13 Granted 200,000 14.73 Vested (14,068 ) 17.77 Forfeited (99,439 ) 19.62 Outstanding, September 30, 2024 370,014 15.91 As of September 30, 2024

Note 7 - Income Taxes

Note 7 - Income Taxes	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7 – Income Taxes: The Company calculates its interim income tax provision in accordance with the accounting guidance for income taxes in interim periods. At the end of each interim period, the Company makes its best estimate of the annual expected effective tax rate and applies that rate to its ordinary year-to-date income or loss. The tax expense or benefit related to significant, unusual, or extraordinary items that will be separately reported or reported net of their related tax effect are individually computed and recognized in the interim period in which those items occur. The computation of the annual expected effective tax rate at each interim period requires certain estimates and assumptions including, but not may For the three September 30, 2024 nine September 30, 2024 three nine September 30, 2024 For the three September 30, 2023 nine September 30, 2023 three nine September 30, 2023

Note 8 - Net Income Per Share

Note 8 - Net Income Per Share	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	8 – Net Income Per Share: The Company’s basic net income per share is computed based on the weighted average number of shares of common stock outstanding for the period. Diluted net income per share includes the effect of the Company’s outstanding stock options, stock appreciation rights, nonvested shares of restricted stock and nonvested performance shares, if the inclusion of these items is dilutive. The following table presents a reconciliation of basic and diluted net income per share for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net income used in the computation of basic and diluted net income per share (in thousands) $ 5,403 $ 3,114 $ 9,915 $ 5,215 Weighted average shares outstanding - basic 16,107,549 15,992,792 16,118,885 15,954,264 Dilutive common stock equivalents 436,441 162,563 470,029 178,568 Weighted average shares outstanding - diluted 16,543,990 16,155,355 16,588,914 16,132,832 Net income per share: Basic $ 0.34 $ 0.19 $ 0.62 $ 0.33 Diluted $ 0.33 $ 0.19 $ 0.60 $ 0.32 Awards to purchase 309,778 and 1,198,603 shares of common stock with weighted average exercise prices of $21.44 and $15.32 per share were outstanding during the three September 30, 2024 2023 not Awards to purchase 335,071 and 1,158,819 shares of common stock with weighted average exercise prices of $21.40 and $15.84 per share were outstanding during the nine September 30, 2024 2023 not

Note 9 - Operating Segment Info

Note 9 - Operating Segment Information	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	OTE 9 – Operating Segment Information : The Company manages and reports the following segments: Branded Products segment: Healthcare Apparel segment: third Contact Centers: Intersegment eliminations include the elimination of revenues and costs from services provided by the Contact Centers segment to the Company’s two not During the fourth 2023, The following tables set forth financial information related to the Company’s operating segments (in thousands): Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total For the Three Months Ended September 30, 2024: Net sales $ 92,547 $ 33,025 $ 25,038 $ (920 ) $ - $ 149,690 Segment EBITDA 10,733 3,773 3,030 - (5,882 ) $ 11,654 Supplemental information: Depreciation and amortization $ 1,446 $ 944 $ 770 $ - $ 92 $ 3,252 Capital expenditures $ 127 $ 259 $ 551 $ - $ - $ 937 Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total For the Three Months Ended September 30, 2023: Net sales $ 83,512 $ 29,649 $ 24,121 $ (1,156 ) $ - $ 136,126 Segment EBITDA 6,958 3,055 4,053 - (4,813 ) 9,253 Supplemental information: Depreciation and amortization $ 1,452 $ 1,064 $ 880 $ - $ 119 $ 3,515 Capital expenditures $ 86 $ 115 $ 157 $ - $ 22 $ 380 Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total For the Nine Months Ended September 30, 2024: Net sales $ 260,911 $ 88,854 $ 73,422 $ (2,919 ) $ - $ 420,268 Segment EBITDA 27,404 7,685 9,157 - (17,402 ) $ 26,844 Supplemental information: Depreciation and amortization $ 4,513 $ 2,837 $ 2,246 $ - $ 276 $ 9,872 Capital expenditures $ 714 $ 986 $ 1,124 $ - $ 87 $ 2,911 Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total For the Nine Months Ended September 30, 2023: Net sales $ 244,955 $ 85,875 $ 68,935 $ (3,704 ) $ - $ 396,061 Segment EBITDA 21,456 6,556 10,098 - (14,526 ) 23,584 Supplemental information: Depreciation and amortization $ 4,826 $ 3,014 $ 2,210 $ - $ 281 $ 10,331 Capital expenditures $ 2,093 $ 641 $ 1,221 $ - $ 68 $ 4,023 The following table reconciles income before income tax expense to Segment EBITDA (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Income before income tax expense $ 6,573 $ 3,274 $ 11,815 $ 5,595 Interest expense 1,569 2,464 4,897 7,658 Depreciation and amortization 3,252 3,515 9,872 10,331 Impairment charge 260 - 260 - Segment EBITDA $ 11,654 $ 9,253 $ 26,844 $ 23,584

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		5. Other Effective November 4, 2024 ( The amendments to both employment agreements, dated July 1, 2021, ( 1 December 31, 2027, ( 2 $400,000 January 1, 2025, ( 3 4 5 6 may 30 7 January 1, 2027, 100% three 8 9 10 six The new bonus plan for each executive is effective as of January 1, 2025, 2025, 2026 2027 2.5% December 31, 2027, 80% 12 12 The amendment adds a sales compensation provision that if the Company sells to an unaffiliated entity all or substantially all of the assets or equity of one not ninety 90 ninety 90 December 31, 2026 x July 1, 2021 ( In connection with the amendments, the Company also awarded shares of restricted stock to Messrs. Himelstein and Leide effective on the Effective Date. Mr. Himelstein was granted 100,000 25,000 2022 “2022 third 2022
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Adopted [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation The accompanying unaudited condensed consolidated financial statements of Superior included herein have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") ("U.S." or "United States") and the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. Intercompany items have been eliminated in consolidation. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10 December 31, 2023 not The Company refers to the condensed consolidated financial statements collectively as “financial statements,” and individually as “statements of comprehensive income (loss),” “balance sheets,” “statements of shareholders’ equity,” and “statements of cash flows” herein.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications The accompanying financial statements for the previous year contain certain reclassifications. Reclassifications impact the reporting of accounts receivable-other within the condensed consolidated balance sheets and statements of cash flows as well as the presentation of segment performance as described within Note 9 no
Derivatives, Policy [Policy Text Block]	Written Put Options During the second 2022, 480, Distinguishing Liabilities from Equity December 31, 2023, twenty-four nine September 30, 2024
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements We consider the applicability and impact of all Accounting Standard Updates (“ASUs”). ASUs not not Recently Issued Accounting Pronouncements Not In November 2023, 2023 07, "Segment Reporting (Topic 280 Improvements to Reportable Segment Disclosures" December 15, 2023, December 15, 2024. 2023 07 December 31, 2024 no not In December 2023, 2023 09, "Income Taxes (Topic 740 Improvements to Income Tax Disclosures" December 15, 2024, January 1, 2025. not not

Note 2 - Inventories (Tables)

Note 2 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, 2024 2023 Finished goods $ 67,416 $ 72,370 Work in process 1,462 671 Raw materials 24,893 25,026 Inventories $ 93,771 $ 98,067

Note 3 - Long-term Debt (Tables

Note 3 - Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	September 30, December 31, 2024 2023 Credit Facilities: Revolving credit facility due August 2027 $ 19,000 $ 25,000 Term loan due August 2027 66,094 69,375 85,094 94,375 Less: Payments due within one year included in current liabilities 5,625 4,688 Debt issuance costs 714 898 Long-term debt less current maturities $ 78,755 $ 88,789

Note 4 - Net Sales (Tables)

Note 4 - Net Sales (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Accounts Receivables and Contract Assets [Table Text Block]	September 30, December 31, 2024 2023 Accounts receivable $ 98,822 $ 103,494 Current contract assets 50,326 48,715 Current contract liabilities 2,845 5,346

Note 6 - Share-based Compensa_2

Note 6 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Stock options and SARs $ 289 $ 319 $ 784 $ 1,018 Restricted stock 582 599 1,550 1,956 Performance shares 414 185 571 549 Total share-based compensation expense $ 1,285 $ 1,103 $ 2,905 $ 3,523
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Aggregate No. of Weighted Average Remaining Life Intrinsic Value Shares Exercise Price (in years) (in thousands) Outstanding, January 1, 2024 953,176 $ 14.73 2.80 $ 1,718 Granted (1) 183,800 14.38 Exercised (122,395 ) 10.71 Lapsed or cancelled (199,984 ) 16.49 Outstanding, September 30, 2024 814,597 14.82 3.26 2,165 Exercisable, September 30, 2024 341,469 18.59 2.22 494
Share-Based Payment Arrangement, Stock Appreciation Right, Activity [Table Text Block]	Weighted Average Aggregate No. of Weighted Average Remaining Life Intrinsic Value Shares Exercise Price (in years) (in thousands) Outstanding, January 1, 2024 292,508 $ 14.35 2.07 $ 506 Granted (1) 79,128 13.84 Exercised (17,920 ) 8.48 Lapsed or cancelled (81,770 ) 19.23 Outstanding, September 30, 2024 271,946 13.12 2.34 832 Exercisable, September 30, 2024 137,742 13.37 0.79 479
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Average No. of Grant Date Shares Fair Value Outstanding, January 1, 2024 428,366 $ 18.14 Granted 146,303 14.77 Vested (79,322 ) 23.71 Forfeited (34,029 ) 19.75 Outstanding, September 30, 2024 461,318 15.99
Schedule of Nonvested Performance-Based Units Activity [Table Text Block]	Weighted Average No. of Grant Date Shares Fair Value Outstanding, January 1, 2024 283,521 $ 18.13 Granted 200,000 14.73 Vested (14,068 ) 17.77 Forfeited (99,439 ) 19.62 Outstanding, September 30, 2024 370,014 15.91

Note 8 - Net Income Per Share (

Note 8 - Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net income used in the computation of basic and diluted net income per share (in thousands) $ 5,403 $ 3,114 $ 9,915 $ 5,215 Weighted average shares outstanding - basic 16,107,549 15,992,792 16,118,885 15,954,264 Dilutive common stock equivalents 436,441 162,563 470,029 178,568 Weighted average shares outstanding - diluted 16,543,990 16,155,355 16,588,914 16,132,832 Net income per share: Basic $ 0.34 $ 0.19 $ 0.62 $ 0.33 Diluted $ 0.33 $ 0.19 $ 0.60 $ 0.32

Note 9 - Operating Segment In_2

Note 9 - Operating Segment Information (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total For the Three Months Ended September 30, 2024: Net sales $ 92,547 $ 33,025 $ 25,038 $ (920 ) $ - $ 149,690 Segment EBITDA 10,733 3,773 3,030 - (5,882 ) $ 11,654 Supplemental information: Depreciation and amortization $ 1,446 $ 944 $ 770 $ - $ 92 $ 3,252 Capital expenditures $ 127 $ 259 $ 551 $ - $ - $ 937 Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total For the Three Months Ended September 30, 2023: Net sales $ 83,512 $ 29,649 $ 24,121 $ (1,156 ) $ - $ 136,126 Segment EBITDA 6,958 3,055 4,053 - (4,813 ) 9,253 Supplemental information: Depreciation and amortization $ 1,452 $ 1,064 $ 880 $ - $ 119 $ 3,515 Capital expenditures $ 86 $ 115 $ 157 $ - $ 22 $ 380 Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total For the Nine Months Ended September 30, 2024: Net sales $ 260,911 $ 88,854 $ 73,422 $ (2,919 ) $ - $ 420,268 Segment EBITDA 27,404 7,685 9,157 - (17,402 ) $ 26,844 Supplemental information: Depreciation and amortization $ 4,513 $ 2,837 $ 2,246 $ - $ 276 $ 9,872 Capital expenditures $ 714 $ 986 $ 1,124 $ - $ 87 $ 2,911 Branded Products Healthcare Apparel Contact Centers Intersegment Eliminations Other Total For the Nine Months Ended September 30, 2023: Net sales $ 244,955 $ 85,875 $ 68,935 $ (3,704 ) $ - $ 396,061 Segment EBITDA 21,456 6,556 10,098 - (14,526 ) 23,584 Supplemental information: Depreciation and amortization $ 4,826 $ 3,014 $ 2,210 $ - $ 281 $ 10,331 Capital expenditures $ 2,093 $ 641 $ 1,221 $ - $ 68 $ 4,023
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Income before income tax expense $ 6,573 $ 3,274 $ 11,815 $ 5,595 Interest expense 1,569 2,464 4,897 7,658 Depreciation and amortization 3,252 3,515 9,872 10,331 Impairment charge 260 - 260 - Segment EBITDA $ 11,654 $ 9,253 $ 26,844 $ 23,584

Note 1 - Description of Busin_2

Note 1 - Description of Business and Basis of Presentation (Details Textual) - Options Held [Member] - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Jun. 30, 2022
Derivative, Underlying Investment, Shares (in shares)			207,970
Derivative, Underlying Investment, Fair Value		$ 1.8	$ 3.6
Open Option Contracts, Expiration Period (Month)			24 months
Derivative, Underlying Investment, Shares, Expirations in Period (in shares)	132,924
Increase (Decrease) in Derivative Liabilities	$ 2.4

Note 2 - Inventories - Inventor

Note 2 - Inventories - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finished goods	$ 67,416	$ 72,370
Work in process	1,462	671
Raw materials	24,893	25,026
Inventories	$ 93,771	$ 98,067

Note 3 - Long-term Debt (Detail

Note 3 - Long-term Debt (Details Textual) - Credit Agreement [Member] $ in Thousands	Aug. 23, 2022 USD ($)	Sep. 30, 2024 USD ($)
Long-Term Debt, Maturity, Remainder of Fiscal Year		$ 1,400
Long-Term Debt, Maturity, Year One		5,600
Long-Term Debt, Maturity, Year Two		6,600
Long-Term Debt, Maturity, Year Three		$ 52,500
Debt Instrument Covenant Fixed Charge Coverage Ratio	1.25
Debt Instrument Covenant, Net Leverage Ratio	4
PNC Bank [Member]
Line of Credit Facility, Additional Capacity Available	$ 75,000
Debt, Weighted Average Interest Rate		6%
PNC Bank [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	0.10%
PNC Bank [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	0.25%
PNC Bank [Member] | Adjusted Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1%
PNC Bank [Member] | Adjusted Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	2%
Revolving Credit Facility [Member]
Letters of Credit Outstanding, Amount		$ 0
Revolving Credit Facility [Member] | PNC Bank [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 125,000
Revolving Credit Facility [Member] | PNC Bank [Member] | Minimum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.125%
Revolving Credit Facility [Member] | PNC Bank [Member] | Maximum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Term Loan [Member] | PNC Bank [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 75,000

Note 3 - Long-term Debt - Long-

Note 3 - Long-term Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Long-term debt, gross	$ 85,094	$ 94,375
Payments due within one year included in current liabilities	5,625	4,688
Debt issuance costs	714	898
Long-term debt less current maturities	78,755	88,789
PNC Bank [Member] | Revolving Credit Facility [Member]
Long-term debt, gross	19,000	25,000
BB&T [Member] | Term Loan Maturing May 2020 [Member]
Long-term debt, gross	$ 66,094	$ 69,375

Note 4 - Net Sales (Details Tex

Note 4 - Net Sales (Details Textual) $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($)
Contract with Customer, Liability, Revenue Recognized	$ 4.9

Note 4 - Net Sales - Accounts R

Note 4 - Net Sales - Accounts Receivable and Contract Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accounts receivable	$ 98,822	$ 103,494
Current contract assets	50,326	48,715
Current contract liabilities	$ 2,845	$ 5,346

Note 5 - Contingencies (Details

Note 5 - Contingencies (Details Textual) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2024	Dec. 31, 2023
Business Combination, Contingent Consideration, Liability, Current	$ 740	$ 740			$ 1,403
Payment for Contingent Consideration Liability, Operating Activities		686	$ 279
Sutter's Mill [Member]
Business Combination, Contingent Consideration, Liability, Current				$ 500
Guardian Products, Inc. [Member]
Business Combination, Contingent Consideration, Liability, Current	700	700
Payment for Contingent Consideration Liability, Operating Activities	1,000
Guardian Products, Inc. [Member] | Minimum [Member]
Business Combination, Contingent Consideration, Liability, Current	900	900
Guardian Products, Inc. [Member] | Maximum [Member]
Business Combination, Contingent Consideration, Liability, Current	$ 1,000	$ 1,000

Note 6 - Share-based Compensa_3

Note 6 - Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions				3 Months Ended	6 Months Ended	9 Months Ended
		May 10, 2024	May 01, 2024	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2024
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						5 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 4.27
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 2.5		$ 2.5
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				1 year 6 months
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 0.8		$ 0.8
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						1 year
Stock Appreciation Rights (SARs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				0.3		$ 0.3
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						1 year
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 3.8
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)	[1]				79,128
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)						3 years
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 3.8		$ 3.8
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						1 year 8 months 12 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 14.77
Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 14.73
Performance Shares [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share based Compensation Arrangement By Share based Payment Award Award Vesting Rights Requirement Percentage Of Closing Share Price		115%
Performance Shares [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share based Compensation Arrangement By Share based Payment Award Award Vesting Rights Requirement Percentage Of Closing Share Price		130%
Performance Shares [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Share based Compensation Arrangement By Share based Payment Award Award Vesting Rights Requirement Percentage Of Closing Share Price		150%
Outside Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						10 years
Michael Benstock [Member] | Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)			125,000
Michael Koempel [Member] | Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)			75,000
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)						1 year
Minimum [Member] | Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)						3 years
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)						3 years
Maximum [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)						5 years
Maximum [Member] | Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)						5 years
[1]The weighted average grant date fair value of SARs granted was $3.80 per share.

Note 6 - Share-based Compensa_4

Note 6 - Share-based Compensation - Share-based Compensation Expense and the Related Tax Benefit (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based compensation expense	$ 1,285	$ 1,103	$ 2,905	$ 3,523
Stock Options and SARs [Member]
Share-based compensation expense	289	319	784	1,018
Restricted Stock [Member]
Share-based compensation expense	582	599	1,550	1,956
Performance Shares [Member]
Share-based compensation expense	$ 414	$ 185	$ 571	$ 549

Note 6 - Share-based Compensa_5

Note 6 - Share-based Compensation - Stock Option Transactions (Details) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares		Dec. 31, 2023 USD ($) $ / shares shares
Outstanding, options (in shares) | shares	953,176
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 14.73
Outstanding, weighted average remaining life (Year)	3 years 3 months 3 days		2 years 9 months 18 days
Outstanding, aggregate intrinsic value | $	$ 2,165		$ 1,718
Granted (in shares) | shares	183,800	[1]
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 14.38
Exercised (in shares) | shares	(122,395)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 10.71
Lapsed or cancelled (in shares) | shares	(199,984)
Lapsed or cancelled, weighted average exercise price (in dollars per share) | $ / shares	$ 16.49
Outstanding, options (in shares) | shares	814,597		953,176
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 14.82		$ 14.73
Exercisable, options (in shares) | shares	341,469
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 18.59
Exercisable, weighted average remaining life (Year)	2 years 2 months 19 days
Exercisable, aggregate intrinsic value, options | $	$ 494
[1]The weighted average grant date fair value of stock options granted was $4.27 per share.

Note 6 - Share-based Compensa_6

Note 6 - Share-based Compensation - Stock-settled Stock Appreciation Rights Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended	9 Months Ended	12 Months Ended
		Jun. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Lapsed or cancelled (in shares)			(199,984)
Lapsed or cancelled, weighted average exercise price (in dollars per share)			$ 16.49
Stock Appreciation Rights (SARs) [Member]
Outstanding SARS (in shares)		292,508	292,508
Outstanding (in dollars per share)		$ 14.35	$ 14.35
Outstanding SARS, weighted average remaining life (Year)			2 years 4 months 2 days	2 years 25 days
Outstanding SARS, aggregate intrinsic value			$ 832	$ 506
Granted SARs (in shares)	[1]	79,128
Granted SARS, weighted average exercise price (in dollars per share)	[1]	$ 13.84
Exercised SARs (in shares)		(17,920)
Exercised SARS, weighted average exercise price (in dollars per share)		$ 8.48
Lapsed or cancelled (in shares)		(81,770)
Lapsed or cancelled, weighted average exercise price (in dollars per share)		$ 19.23
Outstanding SARS (in shares)		271,946		292,508
Outstanding SARS, weighted average exercise price (in dollars per share)		$ 13.12		$ 14.35
Exercisable (in shares)		137,742
Exercisable, weighted average exercise price (in dollars per share)		$ 13.37
Exercisable SARS, weighted average remaining life (Year)			9 months 14 days
Exercisable, aggregate intrinsic value			$ 479
[1]The weighted average grant date fair value of SARs granted was $3.80 per share.

Note 6 - Share-based Compensa_7

Note 6 - Share-based Compensation - Restricted Stock Transactions (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Outstanding (in shares) | shares	428,366
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 18.14
Granted (in shares) | shares	146,303
Granted, weighted average grant date fair value (in dollars per share) | $ / shares	$ 14.77
Vested (in shares) | shares	(79,322)
Vested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 23.71
Forfeited (in shares) | shares	(34,029)
Forfeited, weighted average grant date fair value (in dollars per share) | $ / shares	$ 19.75
Outstanding (in shares) | shares	461,318
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 15.99

Note 6 - Share-based Compensa_8

Note 6 - Share-based Compensation - Performance Share Transactions (Details) - Performance Shares [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Outstanding (in shares) | shares	283,521
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 18.13
Granted (in shares) | shares	200,000
Granted, weighted average grant date fair value (in dollars per share) | $ / shares	$ 14.73
Vested (in shares) | shares	(14,068)
Vested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 17.77
Forfeited (in shares) | shares	(99,439)
Forfeited, weighted average grant date fair value (in dollars per share) | $ / shares	$ 19.62
Outstanding (in shares) | shares	370,014
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 15.91

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Expense (Benefit)	$ 1,170	$ 160	$ 1,900	$ 380
Effective Income Tax Rate Reconciliation, Percent	17.80%	4.90%	16.10%	6.80%

Note 8 - Net Income Per Share_2

Note 8 - Net Income Per Share (Details Textual) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	309,778	1,198,603	335,071	1,158,819
Antidilutive Securities Excluded from Computation of Earnings Per Share, Weight Average Exercise Price (in dollars per share)	$ 21.44	$ 15.32	$ 21.4	$ 15.84

Note 8 - Net Income Per Share -

Note 8 - Net Income Per Share - Reconciliation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net income	$ 5,403	$ 3,114	$ 9,915	$ 5,215
Basic (in shares)	16,107,549	15,992,792	16,118,885	15,954,264
Dilutive common stock equivalents (in shares)	436,441	162,563	470,029	178,568
Weighted average shares outstanding - diluted (in shares)	16,543,990	16,155,355	16,588,914	16,132,832
Basic (in dollars per share)	$ 0.34	$ 0.19	$ 0.62	$ 0.33
Diluted (in dollars per share)	$ 0.33	$ 0.19	$ 0.6	$ 0.32

Note 9 - Operating Segment In_3

Note 9 - Operating Segment Information - Information Related to the Operations of the Company's Operating Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net sales	$ 149,690	$ 136,126	$ 420,268	$ 396,061
Segment EBITDA	11,654	9,253	26,844	23,584
Depreciation and amortization	3,252	3,515	9,872	10,331
Capital expenditures	937	380	2,911	4,023
Depreciation and amortization	3,252	3,515	9,872	10,331
Net sales	149,690	136,126	420,268	396,061
Depreciation and amortization	3,252	3,515	9,872	10,331
Capital expenditures	937	380	2,911	4,023
Operating Segments [Member] | Branded Products [Member]
Net sales	92,547	83,512	260,911	244,955
Segment EBITDA	10,733	6,958	27,404	21,456
Depreciation and amortization	1,446	1,452	4,513	4,826
Capital expenditures	127	86	714	2,093
Depreciation and amortization	1,446	1,452	4,513	4,826
Net sales	92,547	83,512	260,911	244,955
Depreciation and amortization	1,446	1,452	4,513	4,826
Capital expenditures	127	86	714	2,093
Operating Segments [Member] | Healthcare Apparel [Member]
Net sales	33,025	29,649	88,854	85,875
Segment EBITDA	3,773	3,055	7,685	6,556
Depreciation and amortization	944	1,064	2,837	3,014
Capital expenditures	259	115	986	641
Depreciation and amortization	944	1,064	2,837	3,014
Net sales	33,025	29,649	88,854	85,875
Depreciation and amortization	944	1,064	2,837	3,014
Capital expenditures	259	115	986	641
Operating Segments [Member] | Contact Centers [Member]
Net sales	25,038	24,121	73,422	68,935
Segment EBITDA	3,030	4,053	9,157	10,098
Depreciation and amortization	770	880	2,246	2,210
Capital expenditures	551	157	1,124	1,221
Depreciation and amortization	770	880	2,246	2,210
Net sales	25,038	24,121	73,422	68,935
Depreciation and amortization	770	880	2,246	2,210
Capital expenditures	551	157	1,124	1,221
Intersegment Eliminations [Member]
Net sales	(920)	(1,156)	(2,919)	(3,704)
Segment EBITDA	0	0	0	0
Depreciation and amortization	0	0	0	0
Capital expenditures	0	0	0	0
Depreciation and amortization	0	0	0	0
Net sales	(920)	(1,156)	(2,919)	(3,704)
Depreciation and amortization	0	0	0	0
Capital expenditures	0	0	0	0
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]
Net sales	0	0	0	0
Segment EBITDA	(5,882)	(4,813)	(17,402)	(14,526)
Depreciation and amortization	92	119	276	281
Capital expenditures	0	22	87	68
Depreciation and amortization	92	119	276	281
Net sales	0	0	0	0
Depreciation and amortization	92	119	276	281
Capital expenditures	$ 0	$ 22	$ 87	$ 68

Note 9 - Operating Segment In_4

Note 9 - Operating Segment Information - Segment Adjusted EBITDA Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income before income tax expense	$ 6,573	$ 3,274	$ 11,815	$ 5,595
Interest expense	1,569	2,464	4,897	7,658
Depreciation and amortization	3,252	3,515	9,872	10,331
Impairment charge	260	0	260	0
Segment EBITDA	$ 11,654	$ 9,253	$ 26,844	$ 23,584